News|Articles|October 4, 2024
Quality by Design (QbD) for Biologics: A CDMO's Perspective
Author(s)Catalent
By integrating QbD into the development process, organizations can achieve robust manufacturing processes, regulatory compliance, and commercial success.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
E&L Challenges in Biologics, Part One
2
E&L Challenges in Biologics, Part Two
3
Chiesi–Aliada Partnership Advances BBB-Crossing Technology for Lysosomal Storage Disorders
4
UK Report Says Persistent Failure to Commercialize R&D Threatens Life Sciences
5
